Compare EE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | ANAB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2022 | 2015 |
| Metric | EE | ANAB |
|---|---|---|
| Price | $39.08 | $53.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $39.20 | ★ $71.67 |
| AVG Volume (30 Days) | 252.5K | ★ 746.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | 0.79 | ★ 91.02 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,228,263,000.00 | $234,603,000.00 |
| Revenue This Year | $23.59 | N/A |
| Revenue Next Year | $24.37 | $52.14 |
| P/E Ratio | $106.14 | ★ N/A |
| Revenue Growth | 44.26 | ★ 157.01 |
| 52 Week Low | $21.29 | $17.11 |
| 52 Week High | $43.18 | $73.30 |
| Indicator | EE | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 43.85 |
| Support Level | $31.76 | $51.67 |
| Resistance Level | $40.18 | $57.70 |
| Average True Range (ATR) | 1.27 | 3.62 |
| MACD | -0.16 | -0.35 |
| Stochastic Oscillator | 61.90 | 33.59 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).